ImageVerifierCode 换一换
格式:PPT , 页数:54 ,大小:1,024KB ,
文档编号:4808970      下载积分:28 文币
快捷下载
登录下载
邮箱/手机:
温馨提示:
系统将以此处填写的邮箱或者手机号生成账号和密码,方便再次下载。 如填写123,账号和密码都是123。
支付方式: 支付宝    微信支付   
验证码:   换一换

优惠套餐
 

温馨提示:若手机下载失败,请复制以下地址【https://www.163wenku.com/d-4808970.html】到电脑浏览器->登陆(账号密码均为手机号或邮箱;不要扫码登陆)->重新下载(不再收费)。

已注册用户请登录:
账号:
密码:
验证码:   换一换
  忘记密码?
三方登录: 微信登录  
下载须知

1: 试题类文档的标题没说有答案,则无答案;主观题也可能无答案。PPT的音视频可能无法播放。 请谨慎下单,一旦售出,概不退换。
2: 本站所有资源如无特殊说明,都需要本地电脑安装OFFICE2007和PDF阅读器。
3: 本文为用户(晟晟文业)主动上传,所有收益归该用户。163文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(点击联系客服),我们立即给予删除!。
4. 未经权益所有人同意不得将文件中的内容挪作商业或盈利用途。
5. 本站仅提供交流平台,并不能对任何下载内容负责。
6. 下载文件中如有侵权或不适当内容,请与我们联系,我们立即纠正。
7. 本站不保证下载资源的准确性、安全性和完整性, 同时也不承担用户因使用这些下载资源对自己和他人造成任何形式的伤害或损失。

版权提示 | 免责声明

1,本文(不稳定型心绞痛和非ST段抬高心梗的治疗课件.ppt)为本站会员(晟晟文业)主动上传,163文库仅提供信息存储空间,仅对用户上传内容的表现方式做保护处理,对上载内容本身不做任何修改或编辑。
2,用户下载本文档,所消耗的文币(积分)将全额增加到上传者的账号。
3, 若此文所含内容侵犯了您的版权或隐私,请立即通知163文库(发送邮件至3464097650@qq.com或直接QQ联系客服),我们立即给予删除!

不稳定型心绞痛和非ST段抬高心梗的治疗课件.ppt

1、Acute Coronary Syndromes:Management of UA/NSTEMIOverview of 2003 Updates to the ACC/AHA Guideline for UA/NSTEMI Assess likelihood of CAD Risk stratification Target therapy:more aggressive treatment in higher-risk patients Anti-ischemic,antithrombotic therapy Invasive vs conservative strategy Dischar

2、ge planning(risk factor modification and long-term medical therapy)ACC/AHA,American College of Cardiology/American Heart Association;UA,unstable angina;NSTEMI,nonST-segment elevation myocardial infarction.Braunwald E,et al.J Am Col.Cardiol.2000;36:970-1062.Acute Management of UA/NSTEMIAnti-Ischemic

3、TherapyOxygen,bed rest,ECG monitoringNitroglycerin-BlockersACE inhibitorsUA,unstable angina;NSTEMI,non-ST-segment elevation myocardial infarction;ECG,electrocardiogram;ACE,angiotensin-converting enzyme.Braunwald E,et al.J Am Coll Cardiol.2000;36:970-1062.Antithrombotic TherapyAntiplatelet therapyAnt

4、icoagulant therapyPossible ACSAspirinAspirin+IV Heparin+IV Platelet GP IIb/IIIa AntagonistDefinite ACS With Invasive Strategy(Catheterization/PCI)or High Risk(IIa)*ClopidogrelAspirin+SQ LMWH*orIV HeparinLikely/Definite ACSClopidogrel*Class IIa:enoxaparin preferred over UFH unless CABG planned within

5、 24 hours.ACC,American College of Cardiology;AHA,American Heart association;ACS,acute coronary syndrome;PCI,percutaneous coronary intervention;SQLMWH,subcutaneous low molecular-weight heparin;IV,intravenous.Braunwald E,et al.J Am Coll Cardiol.2000;36:970-1062.ACC/AHA Class I Recommendations for Anti

6、thrombotic Therapy*17.16.5*PlaceboASA05101520Patients(%)Unstable Angina 25.011.0*ASA01020303.31.9*ASA0123411.89.4*ASA051015Acute MIAspirin in Acute Coronary Syndromes*P.0001Death or MI*P=.003Reocclusion*P=.012MI*P.001DeathN=3973995134198587860085878600MI,myocardial infarction;ASA,acetylsalicylic aci

7、d;RISC,Research on InStability in Coronary artery disease.RISC Group.Lancet.1990;336:827-830.Roux S,et al.J Am Coll Cardiol.1992;19:671-677.ISIS-2.Lancet.1988;2:349-360.PlaceboPlaceboPlaceboAspirin in Acute Coronary Syndromes12.93.9*ASA05101511.93.3*ASA05101512.96.2*ASA0510152.21.3*ASA00.511.522.5UA

8、/NSTEMIPrimary PreventionStable Angina*P.0001MI*P=.0003MI*P=.008Death or MI*P=.012Death or MIN=1103411037155178279276118121MI,myocardial infarction;ASA,acetylsalicylic acid;RISC,Research on InStability in Coronary artery disease;ISIS-2,Second International Study of Infarct Survival.PHS.N Engl J Med.

9、1989;321:129-35.Ridker PM,et al.AJC.1991;114:835-839.Cairns JA,et al.N Engl J Med.1985;313:1369-1375.Theroux P,et al.N Engl J Med.1988;319:1105-1111.PlaceboPlaceboPlaceboPlaceboPatients(%)Indirect Comparisons of ASA Doses on Vascular Events in High-Risk Patients*Odds reduction.Treatment effect P.000

10、1.ASA,acetylsalicylic acid.Adapted with permission from BMJ Publishing Group.Antithrombotic Trialists Collaboration.BMJ.2002;324:71-86.0.51.01.52.0500-1500 mg34 19160-325 mg19 2675-150 mg12 32162 mg/d(n=2179)Primary end point16.418.6Death,MI,stroke6.26.1Death2.81.7MI2.02.1Stroke2.12.8Urgent hospital

11、 care9.510.6Urgent resuscitation7.310.0Internal bleeding2.43.3Any bleeding11.115.4Transfusion1.02.0Clopidogrel+ASA(N=6259)Placebo+ASA*(N=6303)CURE:Major Bleeding at 1 year by ASA Dose 200 mg(N=4110)3.7%4.9%P value for trend.0001.0009*P=.0001.P=.0009.Adapted from Peters RJG,et al.Circulation.2003;108

12、:1682-1687.ASA DoseRR:Death/MIASA Alone 68/655=10.4%Heparin+ASA 55/698=7.9%BBBBBBB0.1110Summary Relative Risk0.67(0.44-0.1.02)TherouxRISCCohen 1990ATACSHoldrightGurfinkelComparison of Heparin+ASA vs ASA AloneASA,acetylsalicylic acid;RISC,Research on InStability in Coronary artery disease;ATACS,Antit

13、hrombotic Therapy in Acute Company Syndromes;RR,relative risk;MI,myocardial infarction.Oler A,et al.JAMA.1996;276:811-815.(with permission)TIMI,Thrombosis in Myocardial Infarction;ESSENCE,Efficacy and Safety of Subcutaneous Enozapam in NonQ-Wave Coronary Events;UHF,unfractionated heparin;ENOX,enoxap

14、arin;MI,myocardial infarction;OR,odds ratio.Antman EM,et al.Circulation.1999;100:1602-1608.(with permission)TIMI IIB/ESSENCE Metanalysis:Enoxaparin vs Unfractionated Heparin8.6 7.1 0.82(0.69-0.97)18 .026.5 5.2 0.79(0.65-0.96)21 .025.3 4.1 0.77(0.62-0.95)23 .021.81.4 0.80(0.55-1.16)20 .24 0.512Day281

15、443UFH(%)ENOX(%)OR(95 CI)Favors ENOXFavors UFHPORDeath or MI%0123456789081624324048566472Patients(%)Hours from Randomization7.3%5.5%RRR 24%P=.026UFH(n=1957)ENOX(n=1953)UHF,unfractionated heparin;ENOX,enoxaparin;RRR,relative risk ratio.Antman EM.Circulation.1999;100:1593-1601.(with permission)TIMI II

16、B:Early Phase Death/MI/Urgent Revasc0123456789081624324048566472Patients(%)Hours from Randomization7.3%5.5%RRR 24%P=.026UFH(n=1957)ENOX(n=1953)4.6%1.8%0%2%4%6%UFHEnoxaparinP=.03Major Bleeds96 HoursINTERACT:Enoxaparin vs Unfractionated Heparin With GP IIb/IIIa InhibitorsGoodman SG,et al.Circulation.2

17、003;107:238-244.9%5%0%2%4%6%8%10%Death/MI30 DaysP=.031UFHEnoxaparinPercentA-Phase Study DesignUA/NSTEMIFinal A visit 30 days Randomize-24 hours Chest pain Min 0 hourMax 120 hourTirofiban+ASA Hour 0Aggressive or conservativecare per local practice20261961ENOX1mg/kg q12 hrUFHWeight-adjustedZZ Treat&Ev

18、aluate for Z-Phase2018195239871 endpoint 7 daysBlazing M.presented at ACC 2003.0102030024681012UFHEnoxaparinUFHENOXDays From RandomizationEvent Rates(%)Day 78.4%(169 events)9.4%(184 events)Blazing M.presented ACC 2003.Enox Test vs OutcomesMoliterno DJ,et al.JACC.2003;42:1132-1139.(with permission)De

19、ath/MI/Urg TVRBleeding302520151050200 250 300 350 400 450 500 550 600200 250 300 350 400 450 500 550 600Probability of MACE(%)Probability of Any Bleeding(%)302520151050ENOX Time(sec)ENOX Time(sec)Direct Thrombin Inhibitor Trialists CollaborationDirect Thrombin Inhibitor Trialists Collaborative Group

20、.Lancet.2002;359:294-302.(with permission)11 RCTS36,000 PtsACS,PCI Death orMyocardialInfarctionDirect ThrombinInhibitorHeparin(N=18,736)(N=17,184)OR(95%Cl)End of treatment7 days30 daysEnd of treatment7 days3 daysDeathMyocardialInfarctionEnd of treatment7 days30 daysEnd of treatment7 days30 daysStrok

21、eMajor bleedingduring treatmentIntracranial bleeding during treatment815(4.3%)883(5.1%)947(5.0%)990(5.8%)1399(7.4%)1409(8.2%)355(1.9%)346(2.0%)422(2.2%)395(2.3%)685(3.6%)642(3.7%)522(2.8%)596(3.5%)601(3.2%)672(3.9%)876(4.7%)917(5.3%)62(0.33%)60(0.35%)72(0.38%)70(0.41%)120(0.64%)110(0.64%)360(1.90%)4

22、03(2.30%)21(0.11%)28(0.16%)0.01.02.0Direct ThrombinInhibitorHeparin Better0.85(0.77-0.94%)0.88(0.80-0.96%)0.91(0.84-0.99%)0.97(0.83-1.13%)1.00(0.87-1.16%)1.01(0.90-1.12%)0.80(0.71-0.90%)0.81(0.72-0.91%)0.87(0.79-0.95%)0.95(0.66-1.35%)0.94(0.68-1.31%)1.01(0.78-1.31%)0.75(0.65-0.87%)0.72(0.42-1.23%)Ea

23、rly invasive strategy+/-GP IIb/IIIa Catheterization within 8 hours of last subcutaneous doseUA/NSTEMIIdentified,LMWH-GP IIb/IIIa+GP IIb/IIIa Catheterization between 8-12 hours of last subcutaneous doseNo additionalUFH or LMWHAdditionalEnoxaparin0.3 mg/kg IV bolusSupplementwith UFH 50U/kg,aim forACT

24、200-250Supplementwith UFH 0.1 g/LCAPTUREPRISM14.810.27.59.105101520TnI 0.1 g/LP0.1P.0014.919.65.25.80510152025HeparinTirofibanHeparinAbciximab+HeparinDeath or MI at 30 days(%)GP IIb/IIIa Inhibition in TnI+Patients by Revascularization:PRISM StudyTnI,troponin I;PRISM,Platelet Receptor Inhibition for

25、Ischemic Syndrome Management study;MI,myocardial infarction.Heeschen C,et al.Lancet.1999;354:1757-1762.(with permission)Death/MI at 30 Days0.37(0.15-0.93)P=.020.30(0.10-0.84)P=.0041612840051015202530Event rate(%)Follow-up(days)No revascularizationRevascularizationHeparinHeparinTirofiban TirofibanGP

26、IIb/IIIa Inhibition in DiabeticsRoffi M,et al.Circulation.2001;104:2767-2771.(with permission)30-Day Mortality in Diabetic Patients2163687362167741211576458PURSUITPRISMPRISM-PLUSGUSTO IVPARAGON APARAGON BPooled6.1%4.2%6.7%7.8%6.2%4.8%6.2%5.1%1.8%3.6%5.0%4.6%4.9%4.6%P=.33P=.07P=.17P=.022P=.51P=.93P=.

27、007TrialNOdds Ratio&95%ClPlaceboIIb/IIIaBreslow-Day:P=.50IIb/IIIa BetterPlacebo BetterOR=0.7400.511.52Intravenous GP IIb/IIIa Antagonists in ACS:Death or MI(at 30 Days)in PCI/CABG 5 Days Cohort and in Medical Treatment Cohort17.310.514.310.102468101214161820InterventionMedical TreatmentDeath or MIPl

28、aceboIV GP IIb/IIIaP=.001P=NS(N=5847)(N=25,555)ACS,acute coronary syndrome;MI,myocardial infarction;PCI,percutaneous coronary intervention;CABG,coronary artery bypass graft;NS,not significant.Boersma E,et al.Lancet.2002;359:189-198.Interaction P.02GP Iib/IIIa Inhibitor NSTE ACS Trials Analysis Risk-

29、Adjusted Mortality at 30 DaysPeterson ED,et al.J Am Coll Cardiol.2003;42:45-53.Boersma E,et al.Lancet.2002;359:189-198.0.52.01.0NRMI1Boersma20.83-1.010.910.79-0.970.8895%CIOdds RatioOdds Ratio for Mortality at 30 DaysGP IIb/IIIa Inhibitor Favored(aspirin+heparin)Control Arm Favored(aspirin+heparin)M

30、ortality by Hospitals Use of Early GP IIb/IIIa Inhibitors(N=1189 Hospitals)Hospital Use of Early GP IIb/IIIa inhibitors in NRMI(%)In-Hospital Mortality(%)3014121086420NRMI,National Registry of Myocardial Infarction.Peterson ED,et al.J Am Coll Cardiol.2003;42:45-53.(with permission)In-Hospital Mortal

31、ity(%)Efficacy of Clopidogrel or Ticlopidine in Reducing Coronary Events After StentingCLASSICS,Clopidogrel Aspirin Stent Intervention Coopoerative Study.Bhatt DL,et al.J Am Coll Cardiol.2002;39:9-14.(with permission)30-Day Major Adverse Cardiac EventsOdds Ratio&95%CITiclopidine BetterClopidogrel Be

32、tterTrialClopid.(%)Ticl.(%)NOverall13,9552.03.90.1110TOPPSCLASSICS101610202.61.33.50.9Lenox HillCCF256523692.45.73.88.9Mller7003.11.7Wessex-3613.45.2N.Memorial13780.82.2S.Illinois8752.11.4Wash.Hosp.8442.00.5Mayo28270.61.6OR=.73,P=.003CURE,Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic

33、Events;MI,myocardial infarction;CV,cardiovascular;RRR,relative risk reduction.Plavix package insert;2002.Adapted with permission(2002)from the Massachusetts Medical Society.Yusuf S,et al.N Engl J Med.2001;345:494-502.0.000.020.040.060.080.100.120.14Cumulative Hazard RateClopidogrel+Aspirin369Placebo

34、+AspirinFollow-up(mo)P=.00009(N=12,562)01220%RRRCURE:Primary End Point MI/Stroke/CV DeathCURE:MI/Stroke/CV Death/Severe Ischemia Within 24 Hours of RandomizationCURE,Clopidogrel in Unstable Angina to Prevent Recurrent Ischemic Events;MI,myocardial infarction;CV,cardiovascular;RRR,relative risk reduc

35、tion;RR,relative risk.Adapted from Yusuf S,et al.Circulation.2003;107:966-972.Hours After RandomizationCumulative Hazard Rates0.00.0050.0100.0150.0200.025024681012141618202224RR=0.67P=.003Placebo+AspirinClopidogrel+Aspirin33%RRRCURE,clopidogrel in Unstable Angina to Prevent Ischemic Events;TIMI,Thro

36、mbosis in Myocardial Infarction;CV,cardiovascular;MI,myocardial infarction;RRR,relative risk reduction;ARR,Absolute risk reduction.*In addition to other standard therapies.Budaj A,et al.Circulation.2002;106:1622-1626.(with permission)Primary Composite End Point(CV Death,MI,Stroke)0510152025304.19.81

37、5.95.711.420.7Low(0-2)Intermediate(3-4)High(5-7)Patients(%)TIMI Risk Stratification29%RRRP.04ARR1.61.64.8 15%RRRP.0327%RRRP.004Placebo+Aspirin*Clopidogrel+Aspirin*CURE:Benefit of Clopidogrel+Aspirin Across All TIMI Risk Score GroupsPCI-CURE:Study DesignCLOPIDOGREL+ASA*PCIPLACEBO+ASA*Open-label thien

38、opyridinePretreatmentOpen-label thienopyridinePretreatmentN=2658 patients undergoing PCIN=1345N=1313CUREPCI-CURERMehta SR,et al.Lancet.2001;358:527-533.30 days post-PCIEnd of follow-upup to 12 months after randomizationPCI CURE:Benefit of Pretreatment With Clopidogrel at 30 Days051015202530Follow-up

39、(days)0.00.020.040.060.0830%RRRP=.03N=2658Cumulative Hazard RateMehta SR,et al.Lancet.2001;358:527-533.(with permission)6.4%4.5%Clopidogrel+ASAPlacebo+ASACardiovascular Death,MI,or Urgent RevascularizationAdapted from Mehta SR,et al.Lancet.2001;358:527-533.(with permission)CV Death or MI From Random

40、ization to End of Follow-upPCI-CURE:Long-term Results0.150.100.050.00100200300400Follow-up(days)12.6%8.8%P=.002N=2658Clopidogrel+AspirinPlacebo+AspirinCumulative Hazard Rates31%Relative RiskReductionSteinhubl S,et al.JAMA.2002;288:2411-2420.Credo Study:Study Design Clopidogrel ArmPlacebo ArmPCI28 Da

41、ysPlacebo+aspirin(325 mg)Pretreatment3-24 h before PCIClopidogrel 300 mg+aspirin(325 mg)Clopidogrel 75 mg QD+aspirin 325 mg QDClopidogrel 75 mg QD+aspirin 325 mg QD12 MonthsPlacebo QD+aspirin(81-325 mg)QDClopidogrel 75 mg QD+aspirin(81-325 mg)QDRObjective:To assess the benefit of 1 year vs 1 month o

42、f clopidogrel plus aspirin in patients undergoing PCIEffect of Timing of Loading Dose:28-Day EndpointDeath,MI,UTVR0.40.60.81.01.2Hazard ratio(95%CI)3 to 6 hrs7.97.0893 6 to 24 hr5.89.4 851 RRR-13.4P=NSRRR 38.6P=.05RRR 18.5P=.23Overall CREDO ResultsN PT-Clopidogrel*No-PT*Events(%)No-PTBetterPT-Clopid

43、ogrelBetterPT,pretreatment;UTVR,urgent target vessel revascularization.*Plus ASA and other standard therapies.Steinhubl S,et al.JAMA.2002;288:2411-2420.CREDO:Benefits of Clopidogrel Plus Aspirin to 1 Year Following PCI CV Death,MI or Stroke*Plus ASA and other standard therapies.Steinhubl S,et al.JAM

44、A.2002;288:2411-2420.(with permission)Combined Endpoint Occurrence(%)Months From Randomization27%RRRP=.02Placebo*Clopidogrel*0510158.5%11.5%036912CURE:Bleeding ResultsCURE,Clopidogrel in Unstable Angina to Prevent Ischemic Events;*Other standard therapies were used as appropriate.Life-threatening an

45、d other major bleeding.Plavix package insert 2003.Event Clopidogrel+Aspirin*(n=6259)(%)Placebo+Aspirin*(n=6303)(%)P ValueMajor bleeding3.7 2.7.001Life-threateningbleeding 2.21.8.13Minor bleeding5.12.4.001Placebo+ASA(%)Clopidogrel+ASA(%)From PCI to 30 daysMajor1.41.6Life threatening0.70.7 Minor0.70.9

46、 From PCI to end of follow-upMajor2.52.7 Life threatening1.31.2 Minor2.13.5P=NS,P=0.03Adapted from Mehta SR,et al.Lancet.2001;358:527-533.PCI-CURE:Bleeding OutcomesMajor/Life-Threatening Bleeds Within 7 Days of CABG SurgeryPlaceboClopidRRPStopped 5 days prior to CABGN=454N=456Pts with Maj/LT Bld TIM

47、I Major5.3%2.4%4.4%1.8%0.830.72.53NSCURE investigators.N Engl J Med.2001;Fox KM.Presented at ESC 2002.CURE:Outcomes by CABG in Initial Hospitalization(CV death/MI/StrokePlaceboClopidogrelN(%)N(%)RRCICABG During Initial Hospitalization:No.of Patients528485 CV death/MI/stroke16.713.20.780.57-1.08No CA

48、BG:No.of Patients57755774 CV death/MI/stroke11.08.90.800.71-0.89CURE investigators.N Engl J Med.2001;Fox KM.Presented at ESC 2002.Early Clopidogrel Timing in ACS PCI-CURE and CREDO:Need to start clopidogrel early(6 h)to get post-PCI benefit 50%-60%of patients get PCI,8%-20%get CABG(half of whom are

49、5 d postcatheterization anyway)Tradeoff per 1000 UA/NSTEMI patient Rx:Early Rx prevents additional 10 major cardiac events vs creating 1.5 TIMI minor bleed post-CABGACS,acute coronary syndrome;PCI,percutaneous coronary intervention;CURE,Clopidogrel in Unstable Angina to Prevent Recurrent Events;CRED

50、O,Clopidogrel for Reduction of Events During Observation;CABG,coronary artery bypass graft;UA,unstable angina;NSTEMI,nonST-segment myocardial infarction;TIMI Thrombosis in Myocardial Infarction.Boersma E,et al.Lancet.2002;359:189-198.PRONTO Study:Effect of Co-Administration of Various Statins With C

侵权处理QQ:3464097650--上传资料QQ:3464097650

【声明】本站为“文档C2C交易模式”,即用户上传的文档直接卖给(下载)用户,本站只是网络空间服务平台,本站所有原创文档下载所得归上传人所有,如您发现上传作品侵犯了您的版权,请立刻联系我们并提供证据,我们将在3个工作日内予以改正。


163文库-Www.163Wenku.Com |网站地图|